Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.
about
A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma.
P2860
Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.
@en
Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.
@nl
type
label
Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.
@en
Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.
@nl
prefLabel
Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.
@en
Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.
@nl
P2860
P356
P1476
Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma
@en
P2093
Ahmad S Halwani
Brian K Link
P2860
P304
P356
10.1586/ERA.11.9
P577
2011-03-01T00:00:00Z